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Objectives The purpose of this study was to evaluate diffuse myocardial fibrosis of the left ventricle (LV) in patients with
atrial fibrillation (AF).
Background Diffuse myocardial fibrosis is a hallmark of cardiomyopathy. Unlike replacement fibrosis, it is not visualized on
delayed-enhancement cardiac magnetic resonance (CMR) imaging, but may be quantified with contrast-
enhanced T1 mapping methods. In atrial fibrillation (AF), it may be induced by arrhythmia or reflect pre-existing
cardiomyopathy.
Methods Ninety subjects underwent CMR using a clinical 1.5-T scanner: 23 controls, 40 paroxysmal AF patients, and 27
persistent AF patients. Cardiac morphology and function was evaluated from CMR cine imaging. A histologically
validated T1 mapping sequence was used to calculate post-contrast T1 relaxation time (T1 time) of the LV myo-
cardium as an index of diffuse myocardial fibrosis.
Results Age was similar across controls, paroxysmal AF patients, and persistent AF patients (54  12 years, 58  9
years, and 56  10 years, p  NS). Persistent AF patients had larger indexed left atrium volume (55  18 ml
vs. 41  12 ml and 47  14 ml) and lower ejection fraction (54  10% vs. 65  6% and 61  8%) than con-
trols and paroxysmal AF patients (p  0.05). Post-contrast ventricular T1 time differed across all groups
(controls, 535  86 ms; paroxysmal AF, 427  95 ms; persistent AF, 360  84 ms; p  0.001). Univariate pre-
dictors of post-contrast ventricular T1 time included age, sex, AF category, ejection fraction, LV mass, congestive
heart failure, and body mass index. After multivariate analysis, age, AF category, and ejection fraction remained
independent predictors.
Conclusions Post-contrast ventricular T1 mapping identifies diffuse LV fibrosis in patients with AF and provides new insights
into the association between AF and adverse ventricular remodeling. (J Am Coll Cardiol 2012;60:2402–8)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.065Diffuse myocardial fibrosis is a hallmark of normal aging
(1), and is also observed in common cardiovascular diseases
including hypertensive heart disease (2), diabetic cardiomy-
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accepted July 24, 2012.opathy (3), and idiopathic dilated cardiomyopathy (4).
Characterized by an increase in collagen and other extracel-
lular matrix components in the interstitium and perivascular
spaces, it represents a reactive process mediated by cardiac
fibroblasts that does not require myocyte necrosis. Func-
tional consequences of diffuse fibrosis are increased myocar-
dial stiffness, diastolic impairment (5,6), and proarrhythmia
due to altered electrophysiologic substrate (7,8).
See page 2409
In contrast to reparative fibrosis, where regional tissue
injury induces focal fibrosis and may manifest as macro-
scopic scar, diffuse interstitial fibrosis cannot be visualized
using conventional cardiac magnetic resonance (CMR)
delayed-enhancement (DE) imaging. Magnetic resonance
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December 11, 2012:2402–8 Diffuse Ventricular Fibrosis in AFimaging (MRI) quantitation of global and regional intersti-
tial fibrosis has recently become possible with the develop-
ment of novel contrast-enhanced T1 mapping techniques
(9–11). The technique of T1 mapping allows direct myocardial
ignal quantification, and has been validated against collagen
ontent in animal models (12,13) and in subjects with cardio-
yopathy (9).
In the setting of atrial fibrillation (AF), diffuse interstitial
brosis may occur as a result of tachycardia-mediated
ardiomyopathy in conjunction with LV dilation and sys-
olic dysfunction (14). Conversely, it may reflect the pres-
nce of a cardiomyopathy that precedes and contributes to
he development of AF. The presence of concurrent AF and
ardiomyopathy has been associated with an increased risk
f heart failure progression and lethal ventricular arrhyth-
ia, independently of ejection fraction (EF) (15–21). How-
ver, little has been published on the relationship between
iffuse fibrosis of the ventricle and AF in humans. In this
resent study, we quantified diffuse fibrosis and evaluated its
eterminants in a population of highly symptomatic patients
ith AF and in healthy controls.
ethods
tudy population. The study was performed at the Alfred
ospital, Victoria, Australia, between October 2009 and
ctober 2011, and was approved by the Alfred Human
esearch Ethics Committee. Healthy volunteers and patients
ith AF were recruited for CMR. The AF group included
atients with symptomatic AF who were resistant to or
ntolerant of at least 1 antiarrhythmic agent and were sched-
led for catheter ablation of AF. The AF subjects were
ategorized as “paroxysmal,” whose episodes were self-
erminating within 7 days, or as “persistent,” whose episodes
asted7 days or required electrical cardioversion. Isolated AF
as defined as AF in the absence of structural heart disease,
ypertension, and diabetes mellitus. Healthy volunteers who
ere not receiving any medications and who had no history of
ardiac disease, hypertension, diabetes, dyslipidemia, smoking,
r any other acute illness were recruited as controls. Subjects
ith claustrophobia or a history of any metallic prosthetic
mplant contraindicating CMR were excluded.
MR protocol. Subjects underwent CMR using a clinical
.5-T MRI scanner (Signa HD 1.5-T, GE Healthcare,
aukesha, Wisconsin). Sequences were acquired during
reath-holds of as long as 15 s. Left ventricular (LV) function
as assessed by a steady-state free precession pulse sequence
repetition time 3.8 ms, echo time 1.6 ms, 30 phases, slice
hickness 8 mm). Delayed hyperenhancement was obtained 10
in after a bolus (0.2 mmol/kg body weight to a maximum of
0 mmol) of gadolinium-diethylene triamine penta-acetic acid
Magnevist, Schering, Berlin, Germany) to identify regional
brosis using an inversion-recovery gradient echo technique
repetition time 7.1 ms, echo time 3.1 ms, inversion time
ndividually determined to null the myocardial signal 180 to50 ms, slice thickness 8 mm,
atrix 256  192, number of
cquisitions 2).
For evaluation of diffuse inter-
titial fibrosis, a T1 mapping se-
quence, described previously (9),
was used to acquire images in
mid-LV short-axis view over a
range of inversion times. This con-
sisted of an electrocardiogram-
triggered, inversion-recovery pre-
pared, 2-dimensional fast gradient
echo sequence employing variable
temporal sampling of k-space
(Global Applied Science Labora-
tory, GE Healthcare) (22). Ten
images were acquired sequentially at increasing inversion times
(75 ms to 750 ms) 15 min post-contrast over a series of 3 to 4
breath-holds using the following imaging parameters: repeti-
tion/echo time 3.7 ms/1.2 ms, flip angle 20°, 256  128
acquisition matrix, 36  27-cm field of view, 8-mm slice
thickness, trigger delay 300 ms, and views per segment 24.
These images were then processed with a curve fitting tech-
nique to generate T1 maps as described in the following text.
All cine CMR sequences were performed in 3 standard
short-axis slices (apical, mid, and basal), kept identical for each
sequence throughout the CMR examination (23). From an
end-diastolic, 4-chamber, long-axis view, 5 equally spaced slices
were planned, so that the 2 outer slices lined up exactly either with
the tip of the apex or the mitral annulus. The 2 outer slices were
then deleted, leaving 3 slices corresponding to typical basal, mid,
and apical short-axis views. Delayed enhancement imaging was
performed in both long- and short-axis views. For T1 mapping,
he mid-LV short-axis slice was utilized.
valuation of LV function and regional fibrosis. The left
entricle function was evaluated globally using the biplane area-
ength method using 2- and 4-chamber long-axis views. Regional
brosis was identified by delayed enhancement within the myo-
ardium, defined quantitatively by myocardial post-contrast signal
ntensity 5 SD above that within a reference region of remote
onfibrotic myocardium within the same slice.
valuation of diffuse fibrosis with T1 mapping. The T1
mapping sequences were analyzed using a dedicated re-
search software package (VizPack Version 7.2.0, Global
Applied Science Laboratory, GE Healthcare). The software
enabled analysis of regions of interest to determine pixel-
by-pixel and mean post-contrast ventricular T1 time by fitting
ata acquired at various preparation times to the exponential
urve Mz(t  TI)  M0(A-Be
-t/T1) relating the sample
agnetization Mz observed at time t  TI to the equilibrium
magnetization M0 and sample T1, where TI denotes inversion
time for an inversion recovery experiment. For each image, an
regions of interest was drawn around the entire LV myocar-
dium along the endocardial and epicardial borders to calculate
post-contrast ventricular T1 time for each subject. To exclude
Abbreviations
and Acronyms
AF  atrial fibrillation
BMI  body mass index
CMR  cardiac magnetic
resonance
DE  delayed enhancement
EF  ejection fraction
LA  left atrial
LV  left ventricular
MRI  magnetic resonance
imaging
NYHA  New York Heart
Associationcontrast kinetics as a confounding factor in the analysis of
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Diffuse Ventricular Fibrosis in AF December 11, 2012:2402–8post-contrast myocardial T1 time, post-contrast T1 time was
determined for the LV blood pool using regions of interest
traced within the LV endocardial border.
Statistics. All data are expressed as mean  SD unless
otherwise indicated. Comparisons between 2 groups were
made using unpaired or paired Student’s t test for continuous
variables and the chi-square test for categorical variables. For
comparisons across 3 groups, 1-way analysis of variance with
Bonferroni correction was used for parametric variables, and
Kruskal-Wallis test with Dunn’s post-hoc test for nonpara-
metric variables. Simple and multiple linear regressions were used
to assess predictors of post-contrast ventricular T1 time, with
categorical values entered into regression analyses using dummy
coding. A p value of  0.05 was considered significant, and all
reported p values are 2-tailed. Analyses were conducted using
SPSS software (version 17, SPSS, Chicago, Illinois).
Results
Subject characteristics. A total of 90 subjects were evalu-
ated in the study period: 23 healthy controls, 40 subjects
with paroxysmal AF, and 27 subjects with persistent AF.
General characteristics are presented in Table 1. Mean age
was similar across controls and AF subjects. Persistent AF
Subject CharacteristicsTable 1 Subject Characteristics
Characteristics
Control
(n  23)
General characteristics
Age, yrs 54 12
Male 12 (52)
CHA2DS2-VaSc score 0.7 0.8
NYHA class II to IV 0 (0)
NYHA class III or IV 0 (0)
NYHA class IV 0 (0)
Resting heart rate, beats/min 58 25
Estimated GFR, ml/min 84 32
Body mass index, kg/m2 25 7
Comorbidities
Congestive heart failure —
Coronary artery disease —
Diabetes mellitus —
Hypertension —
Smoking —
Medications
ACE inhibitor or ARB —
Aldosterone antagonist —
Beta-blocker —
Calcium-channel blocker —
Digoxin —
Furosemide —
Statin —
Warfarin —
Antiarrhythmics tried —
Values are mean  SD or n (%). *Significant difference compared to
fibrillation (AF) group.
ACE  angiotensin-converting enzyme; ARB  angiotensin recepto
years, diabetes, stroke, vascular disease, age 65 to75 years, sex category (f
GFR  glomerular filtration rate; NYHA  New York Heart Association.subjects had greater mean CHA2DS2-VaSc score (1 point
each for congestive heart failure, hypertension, age 65 to 75
years, diabetes, stroke, vascular disease, and female sex cate-
gory; 2 points each for age75 years and previous stroke) than
controls and paroxysmal AF subjects. Both AF groups had
worse New York Heart Association (NYHA) functional class
than controls. Persistent AF subjects more frequently had a
history of congestive heart failure, and were more frequently
prescribed angiotensin-converting enzyme inhibitors (or
angiotensin-receptor blockers), aldosterone antagonists, furo-
semide, and warfarin than were paroxysmal AF subjects. At the
time of CMR, there were no significant differences across
controls, paroxysmal AF subjects, and persistent AF subjects in
resting heart rate, body mass index (BMI), estimated glomer-
ular filtration rate (24), or cardiovascular comorbidities.
Cardiac morphology, function, and regional fibrosis.
Morphological and functional data are presented in Table 2.
Persistent AF subjects had significantly lower LV EF
compared with controls and paroxysmal AF subjects. Left
ventricular end-diastolic volume and LV mass were higher
in persistent AF subjects compared with controls, but not
after correction for body surface area. Left atrial (LA)
volume and indexed LA volume were greater in persistent
aroxysmal AF
(n  40)
Persistent AF
(n  27) p Value
58 9 56 10 0.23
27 (68) 22 (81) 0.09
1.4 1.2 1.5 1.0* 0.05
22 (55)* 18 (67)* 0.0001
6 (15) 4 (15) 0.15
1 (3) 1 (4) 0.67
61 29 61 26 0.85
86 24 89 27 0.76
28 5 28 5 0.15
4 (10) 14 (52)† 0.001
6 (15) 5 (19) 0.73
2 (5) 1 (4) 1.00
17 (42) 9 (33) 0.60
3 (8) 2 (7) 1.00
14 (35) 20 (74)† 0.01
1 (3) 5 (19)† 0.05
24 (60) 21 (78) 0.19
3 (8) 7 (26) 0.08
7 (18) 7 (26) 0.54
1 (3) 5 (19)† 0.05
9 (23) 3 (11) 0.33
10 (25) 18 (67)† 0.001
1.5 0.6 1.1 0.4† 0.05
trol group. †Significant difference compared to the paroxysmal atrial
r; CHA2DS2-VaSc  congestive heart failure, hypertension, age 75P
the con
r blocke
emale) (1 point each; 2 points for age75 years and previous stroke);
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December 11, 2012:2402–8 Diffuse Ventricular Fibrosis in AFAF subjects versus controls. There was no significant
difference between the paroxysmal and persistent AF groups
in the proportion of subjects with delayed enhancement. Of
the 5 patients with delayed enhancement, 3 had prior myocar-
dial infarcts each involving DE in 1 of 16 segments; 1 subject
had a small region of DE in the basal inferolateral wall of
uncertain significance; and 1 subject had extensive DE in 5
segments involving the inferior, septal, and anterior walls that
was consistent with hypertrophic cardiomyopathy. No other
patients had a diagnosis of hypertrophic cardiomyopathy.
Post-contrast ventricular T1 time in controls and AF
subjects. Post-contrast ventricular T1 time was shortened
n subjects with paroxysmal AF and persistent AF compared
o controls (Fig. 1). Paroxysmal AF subjects also had shorter
ean post-contrast ventricular T1 time than persistent AF
Figure 1 Post-Contrast Ventricular T1
Time in Control and AF Subjects
Post-contrast ventricular T1 time was different across all 3 groups: healthy
controls (535  86 ms, n  23), paroxysmal atrial fibrillation (AF) subjects
(427  95 ms, n  40), and persistent AF subjects (360  84 ms, n  27).
Differences remained significant subjects with delayed enhancement (5) were
excluded from the analysis (535  86 ms vs. 425  98 ms vs. 356  86 ms,
p  0.001). Post-contrast T1 time of the left ventricular blood pool did not vary signifi-
cantly across the 3 groups (262  28 ms vs. 252  35 ms vs. 239  43 ms,
p  NS).
Cardiac Morphology, Function, and Regional FibTable 2 Cardiac Morphology, Function, and
Control
(n  23)
LV ejection fraction, % 65 6
LV end-diastolic volume, ml 145 35
LV end-diastolic volume index, ml/m2 76 14
LV mass, g 103 29
LV mass index, g/m2 54 11
LA volume, ml 80 22
LA volume index, ml/m2 41 12
Delayed enhancement 0 (0)
Values are mean  SD or n (%). *Significant difference compared to
fibrillation (AF) group.
LA  left atrial; LV  left ventricular.ubjects did. All differences in post-contrast ventricular T1 time
across controls, paroxysmal AF subjects, and persistent AF
subjects remained significant after exclusion of the 5 scans of
subjects with delayed enhancement from the comparison.
Mean post-contrast T1 time of the LV blood pool did not vary
significantly across the 3 groups, excluding potential differences
in contrast kinetics across the 3 groups as a confounder to the
measurement of post-contrast myocardial T1 time. Among
controls, there was a significant inverse relationship between
advancing age and post-contrast ventricular T1 time (Fig. 2).
fter univariate analysis, age and resting heart rate (p  0.1)
ere entered into a multivariate model, which yielded only age
s a significant independent predictor of post-contrast ventric-
lar T1 time among controls (Table 3).
nivariate and multivariate correlations with post-
ontrast ventricular T1 time. Relationships with post-
contrast ventricular T1 time were evaluated for the entire study
cohort using simple and multiple linear regressions (Table 4).
After univariate regression, diagnosis of AF of any class,
persistent AF class, LV EF, congestive heart failure, and BMI
(p 0.1) were entered into a multivariate model together with
Figure 2 Relationship Between Post-Contrast Ventricular
T1 Time and Age Among Healthy Control Subjects
In control subjects (n  23), post-contrast ventricular T1 time
decreased with advancing age (R2  0.21, p  0.001).
onal Fibrosis
Paroxysmal AF
(n  40)
Persistent AF
(n  27) p Value
61 8 54 10*† 0.001
160 41 179 33* 0.01
79 17 86 17 0.08
111 25 128 38* 0.05
55 11 61 19 0.12
100 32 114 41* 0.01
47 14 55 18* 0.05
2 (5) 3 (11) 0.22
trol group. †Significant difference compared to the paroxysmal atrialrosisRegi
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Diffuse Ventricular Fibrosis in AF December 11, 2012:2402–8age, which yielded only age, AF class, and LV EF as indepen-
dent correlates of post-contrast ventricular T1 time.
Post-contrast ventricular T1 time and characteristics of
subjects with isolated AF. Characteristics of subjects with
isolated AF (n  12) and age- and sex-matched controls
(n  12) are summarized in Table 5. Paired comparisons
showed no significant differences in CHA2DS2-VaSc score,
esting heart rate at the time of CMR, BMI, or estimated
lomerular filtration rate across the 2 groups. Subjects with
solated AF had worse NYHA functional class, and greater
ndexed LV end-diastolic volume and indexed LA volume.
here were no significant differences in LV EF or LV mass
ndex across the 2 groups, and no subject had delayed
nhancement. Post-contrast ventricular T1 time was short-
ened in subjects with isolated AF compared with age- and
sex-matched controls, whereas post-contrast T1 time of the
LV blood pool was similar across the 2 groups (Fig. 3).
Discussion
In this study, a previously histologically validated contrast-
enhanced magnetic resonance T1 mapping sequence was
used to quantify diffuse interstitial myocardial fibrosis of the
left ventricle in a cohort of highly symptomatic AF patients
Relationship Between Post-Contrast Ventricular T1 Time and SubjeTable 3 Relationship Between Post-Contrast Ventricular T1 Tim
Univariate Model
F R2 p Value
Age† 5.66 0.21 0.05
Male* 0.04 0.00 0.83
Body mass index 0.97 0.04 0.33
Resting heart rate† 3.29 0.15 0.09
Estimated GFR 1.31 0.06 0.27
*Categorical variables were entered into analyses using dummy coding. †Univariate predictors wi
GFR  glomerular filtration rate.
Relationships With Post-Contrast Ventricular T1 TimeTable 4 Relationships With Post-Contrast Ventricular T1 Time
Univariate Model
F R2 p Value
Age† 2.28 0.03 0.13
Male* 2.41 0.02 0.12
Any AF*† 34.91 0.28 0.001
Persistent AF*† 24.73 0.22 0.001
LV EF† 22.62 0.20 0.001
LV EDV index 1.26 0.01 0.26
LV mass index 0.36 0.00 0.55
LA volume index 1.09 0.02 0.30
Hypertension* 0.06 0.00 0.81
Diabetes mellitus* 0.16 0.00 0.69
CAD* 0.74 0.01 0.39
CHF*† 12.11 0.12 0.001
Body mass index† 6.00 0.06 0.05
Resting heart rate 0.84 0.01 0.36
Estimated GFR 0.27 0.00 0.61*Categorical variables were entered into analyses using dummy coding. †Age and univariate predictors w
CAD  coronary artery disease; CHF  congestive heart failure; EDV  end-diastolic volume; EF  ejeand healthy controls. The major finding of this study is that
AF category, along with advancing age, and declining LV
EF, is independently associated with increasing diffuse
fibrosis. Furthermore, a subset of patients with isolated AF
demonstrated diffuse fibrosis suggesting that AF itself may
play an independent role in adverse cardiac remodeling.
Ventricular fibrosis is a key pathologic feature of many
heart diseases. It may occur in a focal distribution due to
regional tissue injury and reparative fibrosis, or in a diffuse
interstitial distribution in the absence of significant myocyte
loss. Whereas cardiac biopsy was previously the only means
available to detect interstitial fibrosis, contrast-enhanced T1
mapping methods now permit its noninvasive quantitation
and play a complementary role to conventional DE-MRI in
the comprehensive assessment of myocardial fibrosis. Post-
contrast myocardial T1 time has been shown to correlate
nversely with histologic assessment of myocardial fibrosis, and
s shortened in patients with heart failure and diabetic cardio-
yopathy where it is associated with diastolic dysfunction
9,25,26). Importantly, in our study, there were no significant
ifferences between study groups in the post-contrast T1 times
of the blood pool, which confirms that the observed differences
in post-contrast myocardial T1 time were not due to differences
aracteristics Among Controlsd Subject Characteristics Among Controls
Multivariate Model
B SE B  p Value
2.9 1.3 0.42 0.05
— — — —
— — — —
2.8 1.7 0.31 0.12
— — — —
lues  0.1 were entered into the multivariate model.
Multivariate Model
B SE B  p Value
1.9 0.9 0.18 0.05
— — — —
75.2 22.8 0.31 0.001
49.2 24.6 0.21 0.05
2.6 1.1 0.22 0.05
— — — —
— — — —
— — — —
— — — —
— — — —
— — — —
24.5 27.8 0.09 0.38
2.4 1.7 0.12 0.16
— — — —
— — — —ct Che anith p values  0.1 were entered into the multivariate model together with age.
ction fraction; other abbreviations as in Tables 1 and 2.
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December 11, 2012:2402–8 Diffuse Ventricular Fibrosis in AFin contrast kinetics among the 3 groups. Given the limited
clinical scenarios in which myocardial tissue sampling is ap-
propriate, little has been published on ventricular fibrosis in
human AF. Frustaci et al. (27) described endomyocardial LV
biopsy findings in 14 patients with lone AF and normal
hemodynamics. Findings were abnormal in all subjects, 6
having myocarditis or cardiomyopathic changes, and notably, 8
having nonspecific interstitial fibrosis. Similarly, in a series of
patients with various supraventricular tachycardias, Kobayashi
et al. (28) demonstrated ventricular fibrosis in 4 of 9 AF
subjects.
In ovine and canine models of cardiac disease, hypertension
and heart failure (conditions associated with diffuse fibrosis)
promote AF through the induction of atrial remodeling
(29,30). Conversely, AF induces systolic heart failure and
ventricular fibrosis through the mechanism of tachycardia-
mediated cardiomyopathy (14). Relevant to the frequently
paroxysmal course of AF is the finding that interstitial fibrosis
may increase during the recovery phase of tachycardia-
mediated cardiomyopathy after normalization of EF (31).
Taken together, these studies suggest that patients with AF may
harbor ventricular fibrosis as a cause or consequence of the
arrhythmia, even when cardiomyopathy is not clinically apparent.
In this study, post-contrast ventricular T1 time shortened
with increasing age, consistent with prior human and animal
studies describing progressive fibrosis of the senescent heart
(1,32). Gazoti Debessa et al. (1) showed collagen content to
increase in the human LV by almost 50% between the third
and seventh decades of life. In the present analysis, healthy
controls and AF patients were of similar age, yet substantial
Characteristics of Subjects WithIsolated AF Versus Age- and Sex-Matched ControlsTable 5 Characteristics of Subjects WithIsolated AF Versus Age- and Sex-Matched Controls
Characteristics
Controls
(n  12)
Isolated AF
(n  12) p Value
General characteristics
Age, yrs 54 9 54 10 0.9
Male 9 (75) 9 (75) 1.0
CHA2DS2-Vasc score 0.4 0.7 0.4 0.6 0.5
NYHA class II to IV 0 (0) 6 (50) 0.05
NYHA class III or IV 0 (0) 3 (25) 0.22
NYHA class IV 0 (0) 0 (0) —
Resting heart rate, beats/min 63 10 66 18 0.8
Body mass index, kg/m2 26 3 26 4 1.0
Estimated GFR, ml/min 90 18 93 12 0.7
Magnetic resonance imaging findings
LV ejection fraction, % 66 6 64 6 0.2
LV end-diastolic volume, ml 143 36 166 22 0.05
LV end-diastolic volume index, ml/m2 73 15 82 8 0.05
LV mass, g 100 23 104 15 0.7
LV mass index, g/m2 51 10 51 5 0.8
LA volume, ml 68 26 99 25 0.01
LA volume index, ml/m2 34 11 49 13 0.01
Delayed enhancement 0 (0) 0 (0) 1.0
Values are mean  SD or n (%).
Abbreviations as in Tables 1 and 2.shortening of post-contrast ventricular T1 time in AFpatients was observed, indicating the presence of diffuse
fibrosis. The LV EF was also an independent predictor, in
line with previous results (9). However, LV hypertrophy,
although an established cause of ventricular fibrosis and
identified as univariate predictor in the analysis, was not an
independent predictor in the present study.
Examination of subjects with isolated AF revealed LV
dilation and diffuse fibrosis compared with age- and sex-
matched healthy persons. Although causal relationships
cannot be established in a cross-sectional study, it is less
likely that AF resulted from occult cardiomyopathy in this
group, given the preservation of LV function and absence of
LV hypertrophy and established causes of diastolic heart
failure. A more plausible explanation is that these patients
fall in the spectrum of AF-mediated cardiomyopathy.
Large-animal models demonstrate that tachycardia-
mediated cardiomyopathy induces LV systolic dysfunction,
dilation, and interstitial fibrosis (14), while its recovery
phase is associated with persistent dilation for as long as 12
weeks after resolution of tachycardia (33) and progression of
interstitial fibrosis (6,31) despite normalization of EF.
Spinale et al. (6) characterized this fibrosis in a canine
model, describing a diffuse increase in hydroxyproline con-
tent, increased collagen type III alpha expression, conflu-
ence of interstitial collagen weave, and thickening of colla-
gen struts and fibrils. In humans, persistence of adverse LV
remodeling has been demonstrated as long as 14 months
after successful tachycardia ablation (34). Thus, structural
LV remodeling in isolated AF may result from accumulated
insults effected by bouts of tachycardia.
Figure 3 Post-Contrast Ventricular T1 Time in Subjects
With Isolated AF and Age- and Sex-Matched Controls
Post-contrast ventricular T1 time was shortened in subjects with isolated atrial
fibrillation (AF) compared with age- and sex-matched controls (430  96 ms
vs. 518  92 ms, p  0.01), whereas post-contrast T1 time of the left ventric-
ular blood pool was similar across the 2 groups (260  28 ms vs. 261  29
ms, p  nonsignificant).
e
s
H
n
p
b
m
T
t
2
2
2
3
3
3
3
3
3
2408 Ling et al. JACC Vol. 60, No. 23, 2012
Diffuse Ventricular Fibrosis in AF December 11, 2012:2402–8Study limitations. Depending on the T1 mapping technique
mployed, estimation of myocardial T1 time may be affected by
ubject parameters such as heart rate and renal function (35).
owever, no differences in these potential confounders were
oted across the 3 study groups, nor did they correlate with
ost-contrast ventricular T1 time on regression analysis. The
higher rate of angiotensin-converting enzyme inhibitor (or angio-
tensin receptor blocker) therapy in patients with persistent AF
may have reduced the extent of diffuse fibrosis in this patient
group. Nonetheless, patients with persistent AF demonstrated a
greater degree of diffuse fibrosis compared to those with paroxys-
mal AF.
Conclusions
Post-contrast T1 mapping identifies diffuse interstitial fi-
rosis of the LV in patients with AF. Ventricular fibrosis
ay either be a cause or consequence of the arrhythmia.
his study provides new insights into the association be-
ween AF and adverse ventricular remodeling.
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